Cargando…
Persistent Spike-specific T cell immunity despite antibody reduction after 3 months from SARS-CoV-2 BNT162b2-mRNA vaccine
Vaccine is the main public health measure to reduce SARS-CoV-2 transmission and hospitalization, and a massive scientific effort worldwide resulted in the rapid development of effective vaccines. This work aimed to define the dynamics and persistence of humoral and cell-mediated immune response in H...
Autores principales: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9034067/ https://www.ncbi.nlm.nih.gov/pubmed/35461335 http://dx.doi.org/10.1038/s41598-022-07741-z |
_version_ | 1784693033439068160 |
---|---|
author | Agrati, Chiara Castilletti, Concetta Goletti, Delia Sacchi, Alessandra Bordoni, Veronica Mariotti, Davide Notari, Stefania Matusali, Giulia Meschi, Silvia Petrone, Linda Aiello, Alessandra Najafi Fard, Saeid Farroni, Chiara Colavita, Francesca Lapa, Daniele Leone, Sara Agresta, Alessandro Capobianchi, Maria Ippolito, Giuseppe Vaia, Francesco Puro, Vincenzo |
author_facet | Agrati, Chiara Castilletti, Concetta Goletti, Delia Sacchi, Alessandra Bordoni, Veronica Mariotti, Davide Notari, Stefania Matusali, Giulia Meschi, Silvia Petrone, Linda Aiello, Alessandra Najafi Fard, Saeid Farroni, Chiara Colavita, Francesca Lapa, Daniele Leone, Sara Agresta, Alessandro Capobianchi, Maria Ippolito, Giuseppe Vaia, Francesco Puro, Vincenzo |
author_sort | Agrati, Chiara |
collection | PubMed |
description | Vaccine is the main public health measure to reduce SARS-CoV-2 transmission and hospitalization, and a massive scientific effort worldwide resulted in the rapid development of effective vaccines. This work aimed to define the dynamics and persistence of humoral and cell-mediated immune response in Health Care Workers who received a two-dose BNT162b2-mRNA vaccination. Serological response was evaluated by quantifying anti-RBD and neutralizing antibodies while cell-mediated response was performed by a whole blood test quantifying Th1 cytokines (IFN-γ, TNF-α, IL-2) produced in response to Spike peptides. BNT162b2-mRNA vaccine induced both humoral and cell-mediated immune response against Spike in all HCW early after the second dose. After 12 weeks from vaccination, the titer of anti-RBD antibodies as well as their neutralization function decreased while the Spike-specific T-cells persisted at the same level as soon after vaccine boost. Of note, a correlation between cellular and humoral response persevered, suggesting the persistence of a coordinated immune response. The long lasting cell-mediated immune response after 3 months from vaccination highlight its importance in the maintaining of specific immunity able to expand again to fight eventual new antigen encountering. |
format | Online Article Text |
id | pubmed-9034067 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-90340672022-04-25 Persistent Spike-specific T cell immunity despite antibody reduction after 3 months from SARS-CoV-2 BNT162b2-mRNA vaccine Agrati, Chiara Castilletti, Concetta Goletti, Delia Sacchi, Alessandra Bordoni, Veronica Mariotti, Davide Notari, Stefania Matusali, Giulia Meschi, Silvia Petrone, Linda Aiello, Alessandra Najafi Fard, Saeid Farroni, Chiara Colavita, Francesca Lapa, Daniele Leone, Sara Agresta, Alessandro Capobianchi, Maria Ippolito, Giuseppe Vaia, Francesco Puro, Vincenzo Sci Rep Article Vaccine is the main public health measure to reduce SARS-CoV-2 transmission and hospitalization, and a massive scientific effort worldwide resulted in the rapid development of effective vaccines. This work aimed to define the dynamics and persistence of humoral and cell-mediated immune response in Health Care Workers who received a two-dose BNT162b2-mRNA vaccination. Serological response was evaluated by quantifying anti-RBD and neutralizing antibodies while cell-mediated response was performed by a whole blood test quantifying Th1 cytokines (IFN-γ, TNF-α, IL-2) produced in response to Spike peptides. BNT162b2-mRNA vaccine induced both humoral and cell-mediated immune response against Spike in all HCW early after the second dose. After 12 weeks from vaccination, the titer of anti-RBD antibodies as well as their neutralization function decreased while the Spike-specific T-cells persisted at the same level as soon after vaccine boost. Of note, a correlation between cellular and humoral response persevered, suggesting the persistence of a coordinated immune response. The long lasting cell-mediated immune response after 3 months from vaccination highlight its importance in the maintaining of specific immunity able to expand again to fight eventual new antigen encountering. Nature Publishing Group UK 2022-04-23 /pmc/articles/PMC9034067/ /pubmed/35461335 http://dx.doi.org/10.1038/s41598-022-07741-z Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Agrati, Chiara Castilletti, Concetta Goletti, Delia Sacchi, Alessandra Bordoni, Veronica Mariotti, Davide Notari, Stefania Matusali, Giulia Meschi, Silvia Petrone, Linda Aiello, Alessandra Najafi Fard, Saeid Farroni, Chiara Colavita, Francesca Lapa, Daniele Leone, Sara Agresta, Alessandro Capobianchi, Maria Ippolito, Giuseppe Vaia, Francesco Puro, Vincenzo Persistent Spike-specific T cell immunity despite antibody reduction after 3 months from SARS-CoV-2 BNT162b2-mRNA vaccine |
title | Persistent Spike-specific T cell immunity despite antibody reduction after 3 months from SARS-CoV-2 BNT162b2-mRNA vaccine |
title_full | Persistent Spike-specific T cell immunity despite antibody reduction after 3 months from SARS-CoV-2 BNT162b2-mRNA vaccine |
title_fullStr | Persistent Spike-specific T cell immunity despite antibody reduction after 3 months from SARS-CoV-2 BNT162b2-mRNA vaccine |
title_full_unstemmed | Persistent Spike-specific T cell immunity despite antibody reduction after 3 months from SARS-CoV-2 BNT162b2-mRNA vaccine |
title_short | Persistent Spike-specific T cell immunity despite antibody reduction after 3 months from SARS-CoV-2 BNT162b2-mRNA vaccine |
title_sort | persistent spike-specific t cell immunity despite antibody reduction after 3 months from sars-cov-2 bnt162b2-mrna vaccine |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9034067/ https://www.ncbi.nlm.nih.gov/pubmed/35461335 http://dx.doi.org/10.1038/s41598-022-07741-z |
work_keys_str_mv | AT agratichiara persistentspikespecifictcellimmunitydespiteantibodyreductionafter3monthsfromsarscov2bnt162b2mrnavaccine AT castilletticoncetta persistentspikespecifictcellimmunitydespiteantibodyreductionafter3monthsfromsarscov2bnt162b2mrnavaccine AT golettidelia persistentspikespecifictcellimmunitydespiteantibodyreductionafter3monthsfromsarscov2bnt162b2mrnavaccine AT sacchialessandra persistentspikespecifictcellimmunitydespiteantibodyreductionafter3monthsfromsarscov2bnt162b2mrnavaccine AT bordoniveronica persistentspikespecifictcellimmunitydespiteantibodyreductionafter3monthsfromsarscov2bnt162b2mrnavaccine AT mariottidavide persistentspikespecifictcellimmunitydespiteantibodyreductionafter3monthsfromsarscov2bnt162b2mrnavaccine AT notaristefania persistentspikespecifictcellimmunitydespiteantibodyreductionafter3monthsfromsarscov2bnt162b2mrnavaccine AT matusaligiulia persistentspikespecifictcellimmunitydespiteantibodyreductionafter3monthsfromsarscov2bnt162b2mrnavaccine AT meschisilvia persistentspikespecifictcellimmunitydespiteantibodyreductionafter3monthsfromsarscov2bnt162b2mrnavaccine AT petronelinda persistentspikespecifictcellimmunitydespiteantibodyreductionafter3monthsfromsarscov2bnt162b2mrnavaccine AT aielloalessandra persistentspikespecifictcellimmunitydespiteantibodyreductionafter3monthsfromsarscov2bnt162b2mrnavaccine AT najafifardsaeid persistentspikespecifictcellimmunitydespiteantibodyreductionafter3monthsfromsarscov2bnt162b2mrnavaccine AT farronichiara persistentspikespecifictcellimmunitydespiteantibodyreductionafter3monthsfromsarscov2bnt162b2mrnavaccine AT colavitafrancesca persistentspikespecifictcellimmunitydespiteantibodyreductionafter3monthsfromsarscov2bnt162b2mrnavaccine AT lapadaniele persistentspikespecifictcellimmunitydespiteantibodyreductionafter3monthsfromsarscov2bnt162b2mrnavaccine AT leonesara persistentspikespecifictcellimmunitydespiteantibodyreductionafter3monthsfromsarscov2bnt162b2mrnavaccine AT agrestaalessandro persistentspikespecifictcellimmunitydespiteantibodyreductionafter3monthsfromsarscov2bnt162b2mrnavaccine AT capobianchimaria persistentspikespecifictcellimmunitydespiteantibodyreductionafter3monthsfromsarscov2bnt162b2mrnavaccine AT ippolitogiuseppe persistentspikespecifictcellimmunitydespiteantibodyreductionafter3monthsfromsarscov2bnt162b2mrnavaccine AT vaiafrancesco persistentspikespecifictcellimmunitydespiteantibodyreductionafter3monthsfromsarscov2bnt162b2mrnavaccine AT purovincenzo persistentspikespecifictcellimmunitydespiteantibodyreductionafter3monthsfromsarscov2bnt162b2mrnavaccine AT persistentspikespecifictcellimmunitydespiteantibodyreductionafter3monthsfromsarscov2bnt162b2mrnavaccine |